- Clinical Trials
- April 2024
- 65 Pages
Global
From €1037EUR$1,050USD£864GBP
€1482EUR$1,500USD£1,234GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1037EUR$1,050USD£864GBP
€1482EUR$1,500USD£1,234GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €865EUR$875USD£720GBP
€1235EUR$1,250USD£1,028GBP
- Report
- March 2024
- 113 Pages
Global
From €5499EUR$5,565USD£4,577GBP
€7855EUR$7,950USD£6,538GBP
- Report
- February 2024
- 30 Pages
Global
€2455EUR$2,485USD£2,044GBP
€3508EUR$3,550USD£2,920GBP
- Report
- February 2024
- 30 Pages
Global
€2455EUR$2,485USD£2,044GBP
€3508EUR$3,550USD£2,920GBP
- Clinical Trials
- February 2024
- 60 Pages
Global
From €865EUR$875USD£720GBP
€1235EUR$1,250USD£1,028GBP
- Report
- January 2024
- 66 Pages
Global
From €2870EUR$2,905USD£2,389GBP
€4101EUR$4,150USD£3,413GBP
- Report
- January 2024
- 132 Pages
Global
From €5499EUR$5,565USD£4,577GBP
€7855EUR$7,950USD£6,538GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €865EUR$875USD£720GBP
€1235EUR$1,250USD£1,028GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €865EUR$875USD£720GBP
€1235EUR$1,250USD£1,028GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €865EUR$875USD£720GBP
€1235EUR$1,250USD£1,028GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €865EUR$875USD£720GBP
€1235EUR$1,250USD£1,028GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €865EUR$875USD£720GBP
€1235EUR$1,250USD£1,028GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €865EUR$875USD£720GBP
€1235EUR$1,250USD£1,028GBP
- Drug Pipelines
- January 2024
- 60 Pages
Global
From €865EUR$875USD£720GBP
€1235EUR$1,250USD£1,028GBP
- Drug Pipelines
- January 2024
- 60 Pages
Global
From €865EUR$875USD£720GBP
€1235EUR$1,250USD£1,028GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €1037EUR$1,050USD£864GBP
€1482EUR$1,500USD£1,234GBP
- Report
- September 2024
- 183 Pages
Global
From €4446EUR$4,500USD£3,701GBP
- Report
- July 2024
- 185 Pages
Global
From €4446EUR$4,500USD£3,701GBP
The Gastrointestinal Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs used to treat diseases and disorders of the gastrointestinal tract. These drugs are used to treat conditions such as irritable bowel syndrome, Crohn's disease, ulcerative colitis, and gastroesophageal reflux disease. Commonly prescribed drugs include antacids, proton pump inhibitors, and H2 receptor antagonists.
The Gastrointestinal Drugs market is highly competitive, with many large pharmaceutical companies vying for market share. Some of the major players in the market include Pfizer, GlaxoSmithKline, Merck & Co., AstraZeneca, and Novartis. These companies are constantly developing new drugs and treatments to meet the needs of patients. Show Less Read more